SENTI BIOSCIENCES INC (SNTI)       2.25  -0.05 (-2.17%)

2.25  -0.05 (-2.17%)

US81726A1007 - Common Stock - After market: 2.25 0 (0%)

SENTI BIOSCIENCES INC2.25

NASDAQ:SNTI (12/2/2022, 7:02:58 PM)-0.05 (-2.17%)

After market: 2.25 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-10 2022-11-10/bmo Earnings (Next) N/A N/A
Ins Owners 9.62% Inst Owners N/A
Market Cap 146.27M Shares 65.01M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82.22
IPO 05-26 2021-05-26

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SNTI Daily chart

Company Profile

Senti Biosciences, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California. The company went IPO on 2021-05-26. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.

Company Info

SENTI BIOSCIENCES INC

2 Corporate Drive, First Floor

South San Francisco CALIFORNIA

P: 16503823281.0

Employees: 0

SNTI News

News Image10 days ago - Senti Biosciences, Inc.Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment...

News Image10 days ago - Senti Biosciences, Inc.Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual MeetingNews Image23 days ago - Senti Biosciences, Inc.Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies...

News Image23 days ago - Senti Biosciences, Inc.Senti Bio Reports Third Quarter Financial Results and Pipeline UpdatesNews Imagea month ago - Senti Biosciences, Inc.Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed...

News Imagea month ago - Senti Biosciences, Inc.Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cells

SNTI Twits

Here you can normally see the latest stock twits on SNTI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example